These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22173446)

  • 1. Tyrosine kinase inhibitors in hematological malignancies.
    Kosior K; Lewandowska-Grygiel M; Giannopoulos K
    Postepy Hig Med Dosw (Online); 2011 Dec; 65():819-28. PubMed ID: 22173446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.
    Klyuchnikov E; Schafhausen P; Kröger N; Brummendorf TH; Osanmaz O; Asenova S; Zabelina T; Ocheni S; Ayuk F; Zander AR; Bacher U
    Acta Haematol; 2009; 122(1):6-10. PubMed ID: 19602874
    [No Abstract]   [Full Text] [Related]  

  • 3. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
    Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F
    J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients.
    Kimura S
    Rinsho Ketsueki; 2009 Jul; 50(7):547-55. PubMed ID: 19638722
    [No Abstract]   [Full Text] [Related]  

  • 5. New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
    Thienelt CD; Green K; Bowles DW
    Drugs Today (Barc); 2012 Sep; 48(9):601-13. PubMed ID: 23032801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
    Melo JV; Chuah C
    Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinase inhibitors in chronic myelogenous leukemia.
    Quintás-Cardama A; Cortes J
    Clin Adv Hematol Oncol; 2006 May; 4(5):365-74. PubMed ID: 16728945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chronic myeloid leukemia].
    Usui N
    Nihon Rinsho; 2014 Jun; 72(6):1068-72. PubMed ID: 25016806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. As leukemia options grow, drugs jockey to be first-line therapies.
    Dolgin E
    Nat Med; 2013 Jan; 19(1):7. PubMed ID: 23295994
    [No Abstract]   [Full Text] [Related]  

  • 11. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase inhibitors: the next generation.
    Fricker J
    Lancet Oncol; 2006 Aug; 7(8):621. PubMed ID: 16900596
    [No Abstract]   [Full Text] [Related]  

  • 13. Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].
    Kantarjian H
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):797-9. PubMed ID: 19194361
    [No Abstract]   [Full Text] [Related]  

  • 14. Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?
    Breccia M
    Nat Rev Clin Oncol; 2010 Oct; 7(10):557-8. PubMed ID: 20877419
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical trials in chronic myeloid leukemia.
    Saussele S; Pfirrmann M
    Curr Hematol Malig Rep; 2012 Jun; 7(2):109-15. PubMed ID: 22422549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
    Kantarjian H; Cortes J
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S37-42; quiz S43-S44. PubMed ID: 18397680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.
    Milojkovic D; Apperley JF; Gerrard G; Ibrahim AR; Szydlo R; Bua M; Reid A; Rezvani K; Foroni L; Goldman J; Marin D
    Blood; 2012 Feb; 119(8):1838-43. PubMed ID: 22174159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Philadelphia-positive acute lymphoblastic leukemia: current treatment options.
    Liu-Dumlao T; Kantarjian H; Thomas DA; O'Brien S; Ravandi F
    Curr Oncol Rep; 2012 Oct; 14(5):387-94. PubMed ID: 22669492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Novel anti-CML agents beyond imatinib].
    Kimura S
    Rinsho Ketsueki; 2007 Jun; 48(6):475-84. PubMed ID: 17633095
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.